Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
320 participants
INTERVENTIONAL
2020-08-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules
NCT01307761
Circulating Biomarkers to Identify Thyroid Cancer
NCT04594720
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
NCT05025046
PACE4 in Thyroid Cancer
NCT03160482
Multiparameter Ultrasound Based-AI for the Diagnosis of Thyroid Nodules
NCT05816629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCT-DIA/MS
PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules
PCT-DIA/MS
PCT-DIA/MS will be validated to classify FNA biopsy specimens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCT-DIA/MS
PCT-DIA/MS will be validated to classify FNA biopsy specimens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with thyroid nodules who have not been treated with drugs;
3. Patients who were diagnosed as Bethesda III and IV by cytology and pathology before operation;
4. Patients who underwent total / partial thyroidectomy and had histopathological reports of corresponding cellular pathological punctured nodules;
5. Patients voluntarily participate in the study after informed consent.
Exclusion Criteria
2. Patients with insufficient FNA sample size (judged by the laboratory).
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Luo Dingcun
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luo Dingcun
vice president of hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dingcun Luo
Role: PRINCIPAL_INVESTIGATOR
First People's Hospital of Hangzhou
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dingcun Luo
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZhejiangU20200701
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.